COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
According to an analysis of COVID-19 hospitalization data from 13 states, released by the Centers for Disease Control and Prevention, 6% of adults hospitalized with COVID-19 between March 1 and May 31 were health care personnel.
The Food and Drug Administration approved Veklury (remdesivir) to treat COVID-19 patients age 12 and older who are hospitalized and weigh at least 40 kilograms (about 88 pounds).
The Department of Health and Human Services (HHS) Oct. 22 issued a revision to its reporting requirements for providers that received Provider Relief Fund (PRF) payments. The notice includes revised data elements that recipients must submit for calendar years 2019 and 2020. Specifically, recipients…
U.S. counties with more racial and ethnic minority residents, people living in crowded housing and other social vulnerabilities were more likely to become COVID-19 hotspots in June and July, according to a study released by the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention updated how it defines “close contact” exposure to an individual infected with the COVID-19 virus to someone within 6 feet of the infected individual for 15 minutes or more cumulatively over a 24-hour period, rather than exposure within 6 feet for at…
A study released by the Centers for Disease Control and Prevention estimates 299,028 more deaths than expected occurred in the United States between Jan. 26 and Oct. 3, with 66% attributed to COVID-19.
Other Events This Week Include HHS Webinars on COVID-19 Data Reporting and AHA Leadership Rounds with AHA Chair Dr. Estes
A national training collaborative that aims to provide every person working in a U.S. healthcare facility the foundation for infection control to protect the nation from infectious disease threats, such as COVID-19.
The Food and Drug Administration Oct. 15 removed epinephrine from the lists of drugs authorized for temporary compounding during the COVID-19 public health emergency by outsourcing facilities and state-licensed pharmacies or federal facilities not registered as outsourcing facilities.
The Food and Drug Administration Oct. 15 said it reissued its emergency use authorization for certain, Chinese-manufactured filtering face-piece respirators that lack National Institute for Occupational Safety and Health approval.